FDA grants priority review to Roche's Tecentriq monotherapy as first-line treatment in certain lung cancer cases Medical Dialogues Bureau20 Feb 2020 2:20 PM ISTBasel: Roche announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and...
Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche Medical Dialogues Bureau25 Nov 2019 9:00 AM ISTMedian overall survival for patients with unresectable hepatocellular carcinoma (HCC), or that which cannot be surgically removed, getting Tecentriq...
Roche Tecentriq, Avastin combo to increase overall survival, progression-free survival in HCC Medical Dialogues Bureau22 Oct 2019 9:50 AM ISTRoche, in its recent release, in 2018, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Tecentriq in...
Gilead Sciences new drug keeps 56 percent of lymphoma trial patients alive Ruby Khatun Khatun11 Dec 2017 10:30 AM ISTMore than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a...
Roche drug cocktail doubles chance of holding lung cancer at bay Ruby Khatun Khatun9 Dec 2017 9:45 AM ISTZURICH: Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease...
Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial Ruby Khatun Khatun1 Dec 2017 9:30 AM ISTFRANKFURT: Germany's Merck KGaA has suffered a setback in the development of key cancer immunotherapy Bavencio, it has failed in a trial to prolong...
Roche win boosts case for adding chemo to cancer immunotherapy Ruby Khatun Khatun23 Nov 2017 9:30 AM ISTLONDON: Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them...
Roche stock up 12 billion dollars on cancer, hemophilia trials; rivals hit Ruby Khatun Khatun22 Nov 2017 10:00 AM ISTZURICH: Roche shares were lifted on Monday by two trial wins for its new cancer and hemophilia drugs, potential blockbusters that the Swiss drugmaker...
Roche cancer immunotherapy Tecentriq wins EU approval Ruby Khatun Khatun25 Sept 2017 10:17 AM ISTZURICH: Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said.The...
